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Ruben Vergara, MD, Emilio V. Dovellini, MD, David Antoniucci, MD
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Objectives The goal of this study was to compare the outcomes of patients treated with everolimus-eluting stents (EES)
with outcomes of patients treated with first-generation paclitaxel-eluting stents (PES) for unprotected left main
disease (ULMD).
Background No data exist about the comparison of these 2 types of stents in ULMD.
Methods The primary endpoint of the study was a 1-year composite of cardiac death, nonfatal myocardial infarction, tar-
get vessel revascularization, and stroke (MACE). Secondary endpoints were 1-year target vessel failure (TVF) and
9-month angiographic in-segment restenosis 50%.
Results From 2004 to 2010, a total of 390 patients underwent ULMD percutaneous coronary intervention (224 received PES
and 166 EES). The 1-year MACE rate was 21.9% in the PES group and 10.2% in the EES group (p  0.002). TVF rate
was 20.5% in the PES group and 7.8% in the EES group (p  0.001). The in-segment restenosis rate was 5.2% in the
EES group and 15.6% in the PES group (p  0.002). EES and EuroSCORE were the only variables related to the risk of
MACE. EES (odds ratio: 0.32; p  0.007) was also independently related to the risk of restenosis.
Conclusions EES implantation for ULMD is associated with a reduced incidence of 1-year MACE, TVF, and restenosis as com-
pared with PES implantation. (J Am Coll Cardiol 2012;60:1217–22) © 2012 by the American College of Cardi-
ology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.038Randomized studies have shown the superiority of the
everolimus-eluting stent (EES) over first-generation
paclitaxel-eluting stents (PES) in non-left main coronary
artery lesions, whereas no data exist about the 2 types of
stents in patients treated for unprotected left main disease
(ULMD) (1–4). The SYNTAX (SYNergy Between PCI
With TAXus and Cardiac Surgery) trial that compared
coronary artery bypass graft surgery with PES-supported
percutaneous coronary intervention (PCI) in patients with
ULMD and/or 3-vessel disease did not met the primary
endpoint of noninferiority of PCI as compared with surgery,
mainly because of the increased rate of repeat revasculariza-
tion in the PCI arm, and it has been hypothesized that the
From the Division of Cardiology, Careggi Hospital, Florence, Italy. The authors have
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disclose.Manuscript received March 21, 2012; revised manuscript received May 25, 2012,
accepted May 28, 2012.use of a more effective stent would have changed the results
of the study (5–7).
The aim of this study was to compare the 2 types of stents
in consecutive patients treated for ULMD.
Methods
The ULMD Florence registry started in 2004 and enrolled
patients treated with drug-eluting stents for ULMD. De-
tails on this registry have been previously published (8,9).
From the registry, we identified patients who received
exclusively EES (either XIENCE V, Abbott Vascular,
Santa Clara, California; or PROMUS, Boston Scientific,
Natick, Massachusetts) or PES (either Taxus Express or
Taxus Liberté, Boston Scientific). The only exclusion cri-
terion from the study was ST-segment elevation myocardial
infarction (MI). Patients underwent PCI instead of coro-
nary surgery because of either the patient’s preference or the
high risk associated with surgery. High surgical risk was
defined as a logistic EuroSCORE 6 (10).
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Stent Comparison for Left Main PCI October 2, 2012:1217–22PCI was performed using
standard techniques. For distal
left main disease, a single-stent
technique was preferred in pa-
tients with a normal or diminutive-
appearing side branch, whereas a
double-stent technique was con-
sidered in patients with disease
of both ostia and proximal seg-
ments of the left anterior de-
scending coronary artery and cir-
cumflex coronary artery. Whatever
the stenting technique used, routine
final kissing balloon post-dilation
with noncompliant balloons had to
be performed in all cases.
Multivessel disease was de-
fined as stenosis 70% of 1
major coronary arteries at baseline angiography besides the
left main lesion. Disease of the left anterior descending
coronary artery and of the circumflex coronary artery in-
cluded lesions beyond 10 mm from the ostia. Completeness
of revascularization was defined as the successful revascu-
larization of all vessels with a diameter stenosis 70% and
a diameter 2 mm achieved either during the index
hospitalization or at any time within 30 days after ULMD
PCI.
Procedural antithrombotic therapy included unfraction-
ated heparin to achieve an activated clotting time of 200 to
250 s, whereas the use of glycoprotein IIb/IIIa inhibitors
was at discretion of the operator. Chronic antithrombotic
treatment included aspirin (300 mg/day indefinitely) and
clopidogrel (75 to 150 mg daily) for at least 1 year.
The primary endpoint of the study was the 1-year major
adverse cardiovascular events (MACE) that included car-
diac death, nonfatal MI, target vessel revascularization
(TVR), and stroke. Secondary endpoints were 1-year target
vessel failure (TVF) and in-segment left main restenosis. All
deaths were considered cardiac unless an unequivocal non-
cardiac cause could be documented. TVF was defined as the
composite of cardiac death, MI not clearly attributable to a
non-left main vessel, and clinically driven ULMD revascu-
larization within 1 year. Stent thrombosis was defined
according to the Academic Research Consortium criteria
(11), whereas restenosis was defined as 50% luminal
narrowing at the segment site including the stent and 5 mm
proximal and distal to the stent edges. Angiographic pa-
rameters were assessed using a computer analysis system
(Innova 2100IQ, General Electric Healthcare Technolo-
gies, Little Chalfont, United Kingdom).
The treatment protocol included routine 6- to 9-month
angiographic follow-up.
The study was approved by the institutional review
committee and all patients gave informed written consent to
Abbreviations
and Acronyms
EES  everolimus-eluting
stent(s)
MACE  major adverse
cardiovascular event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
TVF  target vessel failure
TVR  target vessel
revascularization
ULMD  unprotected left
main diseaseintervention and the study. aStatistical analysis. On the basis of the results of previous
studies (8,9,12,13), we assumed PES to be associated with
MACE and TVF rates of 22% and 20%, respectively. We
hypothesized a 50% reduction in both endpoints with
EES. To achieve a statistical power 80%, a sample size of
at least 160 patients per group was needed, considering an
experimental type I error of 0.05.
Discrete data were summarized as frequencies, and con-
tinuous data were expressed as mean  SD or median and
interquartile range as appropriate. The chi-square test was
used for comparison of categorical variables, and the un-
paired 2-tailed Student t test or Mann-Whitney rank sum
test was used to test differences among continuous variables.
Survival curves were generated with the use of the Kaplan-
Meier method, and the difference between groups was
assessed by log-rank test. The multivariable analysis for the
primary endpoint was performed by the forward stepwise
Cox proportional hazards model, whereas for angiographic
restenosis, analysis was by forward stepwise logistic regres-
sion. The following variables were tested: age (years), male
sex, diabetes mellitus, EuroSCORE, previous MI, right
coronary artery chronic total occlusion, left main stenting of
both branches, minimal lumen diameter post-PCI (mm),
maximum pressure inflation (atm), completeness of revas-
cularization, year of the index procedure, and EES. Inter-
action between EES and year of the index procedure was
tested with the Cox regression model. A propensity score–
matched analysis (1:1) was also performed because of
expected differences in baseline characteristics between pa-
tients receiving EES and patients receiving PES due to
broader indication to PCI in the last years. An optimal
data-matching technique was performed using the propen-
sity score as calipers. Propensity score analysis was per-
formed with the use of a logistic regression model from
which the probability for the use of EES was calculated for
each patient. The variables entered into the model were: age
(years), male sex, serum creatinine 150 mol/l, history of
I, left ventricular ejection fraction 40%, peripheral
ascular disease, EuroSCORE, left main stenting of both
ranches, and left main stent length 24 mm. Model
iscrimination was assessed with the c-statistic and good-
ess of fit with the Hosmer-Lemeshow test. All tests were
-sided, and a p value 0.05 was considered significant.
nalyses were performed using the software package SPSS
ersion 11.5 (SPSS, Chicago, Illinois).
esults
rom 2004 to 2010, 470 patients underwent left main PCI
ith drug-eluting stents. Of these, 390 patients received
xclusively PES or EES (224 received PES and 166 EES).
The majority of patients were at high surgical risk. In the
ES group, there was a higher incidence of hypercholester-
lemia, peripheral vascular disease, and renal insufficiency
nd a higher EuroSCORE, as compared with the EES
tion; P
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October 2, 2012:1217–22 Stent Comparison for Left Main PCIgroup, whereas distal ULMD was more frequent in the
EES group (Table 1).
There were no differences in procedural characteristics
but the final pressure inflation, which was higher in the EES
group than in the PES group (21.6  2.6 atm and 19.6 
2.8 atm, respectively; p  0.001) (Table 2).
Baseline Clinical and Angiographic CharacteristTable 1 Baseline Clinical and Angiographic
Overall
(N  390)
Age, yrs 71.0 10.1
Male 307 (79)
Current smokers 68 (17)
Arterial hypertension 289 (74)
Diabetes mellitus 107 (27)
Hypercholesterolemia 237 (61)
Peripheral vascular disease 107 (27)
Previous myocardial infarction 83 (21)
Previous PCI 135 (35)
Unstable angina 174 (45)
NSTEMI 63 (16)
Creatinine 150 mol/l 66 (17)
LVEF, % 44 13
LVEF 40% 146 (37)
EuroSCORE 6.8 [3.3–18.2]
EuroSCORE 13 121 (31)
LM plus 2-vessel disease) 167 (43)
LM plus 3-vessel disease 117 (30)
Distal LM location 337 (86)
RCA disease 247 (63)
RCA total occlusion 89 (23)
Values are mean  SD, n (%), or median [interquartile range].
EES  everolimus-eluting stent(s); EuroSCORE  European System
left ventricular ejection fraction; PCI  percutaneous coronary interven
myocardial infarction; RCA  right coronary artery.
Procedural CharacteristicsTable 2 Procedural Characteristics
Overall
(N  390)
Ostial/shaft LM stenting only 53 (14)
Distal LM
Single stent 216 (64)
Stenting of both branches 121 (36)
T-stenting 74
Crush stenting 42
V-stenting/culotte stenting 5
Total LM stent length, mm 22 11
IVUS guidance 205 (53)
Abciximab 206 (53)
IABP 40 (10)
Maximum pressure inflation, atm 20.4 2.9
RVD pre-PCI, mm 3.72 0.38
MLD post-PCI, mm 3.75 0.34
Multivessel PCI 239 (61)
Complete revascularization 307 (77)
Values are n (%) or mean  SD.
IABP  intra-aortic balloon pump; IVUS  coronary intravascular ultrasou
lumen diameter; RVD  reference vessel diameter; other abbreviations as inThe majority of patients in both groups had multivessel
PCI and a complete coronary revascularization.
The 1-year clinical follow-up rate was 100% (median
follow-up length: 17.7 months). The incidence of the
primary endpoint rate was 21.9% in the PES group and
10.2% in the EES group (p  0.002) (Table 3).
acteristics
PES
(n  224)
EES
(n  166) p Value
71.2 9.8 70.7 10.5 0.645
179 (80) 128 (77) 0.504
46 (20) 22 (13) 0.061
174 (78) 115 (69) 0.061
67 (30) 40 (24) 0.203
148 (66) 89 (54) 0.013
73 (33) 34 (21) 0.008
54 (24) 29 (18) 0.222
69 (31) 65 (40) 0.066
107 (48) 67 (40) 0.146
42 (19) 21 (13) 0.106
49 (22) 17 (10) 0.002
44 14 46 12 0.296
91 (41) 55 (33) 0.131
7.7 [3.5–21.6] 6.1 [2.8–12.5] 0.011
81 (36) 40 (24) 0.011
99 (44) 68 (41) 0.523
60 (26) 57 (34) 0.108
186 (86) 151 (91) 0.030
149 (66) 98 (59) 0.130
51 (23) 38 (23) 0.977
iac Operative Risk Evaluation; LM left main coronary artery; LVEF
ES  paclitaxel-eluting stent(s); NSTEMI  non–ST-segment elevation
PES
(n  224)
EES
(n  166) p Value
36 (16) 17 (10) 0.076
113 (60) 103 (69) 0.086
75 (40) 46 (31) 0.086
54 20
16 26
5 0
22 12 22 11 0.912
110 (49) 95 (57) 0.112
121 (54) 85 (51) 0.582
20 (10) 20 (12) 0.315
19.6 2.8 21.6 2.6 0.001
3.70 0.40 3.74 0.40 0.219
3.75 0.34 3.82 0.35 0.073
129 (58) 110 (66) 0.082
172 (77) 135 (81) 0.279icsChar
for Cardnd; LAD  left anterior descending coronary artery; MLD  minimal
Table 1.
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Stent Comparison for Left Main PCI October 2, 2012:1217–22The difference in MACE rate was mainly driven by the
TVR rate, which was significantly lower in the EES group
(4.2% vs. 13.4%, p  0.002). Figure 1 shows the MACE-
free survival curves. The long-term event-free survival rate
was 84  4% in the EES group and 68  4% in the PES
group (p  0.006). There was no significant interaction
between EES and year of the index procedure. At multi-
variable analysis, EES (hazard ratio: 0.56; 95% confidence
interval [CI]: 0.33 to 0.96; p  0.034) and EuroSCORE
(hazard ratio: 1.03; 95% CI: 1.02 to 1.04; p  0.001) were
related to the risk of MACE. The TVF rate was 20.5% in
Clinical and Angiographic OutcomesTable 3 Clinical and Angiographic Outcomes
1-Year Clinical Outcome
Overall
(N  390)
PES
(n  224)
MACE 66 (17) 49 (21.9)
Death 24 (6.2) 16 (7.1)
MI 3 (0.8) 1 (0.5)
TVR 37 (9.5) 30 (13.4)
PCI 35 28
CABG 2 2
Stroke 2 (0.5) 2 (0.9)
TVF 59 (15.1) 46 (20.5)
Stent thrombosis 15 (3.8) 12 (5.4)
Definite/probable 2 2
Possible 13 10
Angiographic outcome (N 364) (n 206)
Follow-up rate 355 (98) 200 (97)
In-segment restenosis 39 (11) 31 (15.6)
Values are n (%) or n.
CABG coronary artery bypass grafting; CI confidence interval; HR hazard ratio; MACEma
essel revascularization; other abbreviations as in Table 1.
Figure 1 Kaplan-Meier Analysis of Freedom From
MACE in Patients Treated With EES or PES
EES  everolimus-eluting stent(s); MACE  major adverse cardiovascular
event(s); PES  paclitaxel-eluting stent(s).the PES group and 7.8% in the EES group (p 0.001). There
was a trend toward a lower stent thrombosis rate in the EES
group.
The angiographic follow-up rate was 98%. The incidence
of in-segment restenosis 50% was 5.2% in the EES group
and 15.6% in the PES group (p  0.002). At logistic
regression analysis, EES implantation (odds ratio: 0.32;
95% CI: 0.14 to 0.73; p  0.007) and EuroSCORE (odds
ratio: 1.02; 95% CI: 1.01 to 1.04; p  0.015) were the only
variables related to the risk of restenosis.
Tables 4 and 5 show the characteristics and the outcome
of the 2 matched patient cohorts (c-statistic: 0.63, and
Hosmer-Lemeshow test: p  0.875, for propensity score
analysis). The incidence of 1-year MACE, TVF, and
restenosis remained significantly higher in the PES group
compared with the EES group (20.4%, 19.3%, and 15.4%,
and 10.2%, 7.8%, and 5.2%, respectively).
Discussion
The main findings of this study can be summarized as
follows: 1) in patients undergoing PCI for ULMD, EES is
associated with a 50% reduction in the incidence of
angiographic restenosis, TVF, and MACE as compared
with PES; 2) the MACE and TVF rate reduction with EES
is mainly driven by a lower recurrence of TVR; and 3) the
relevant reduction of clinical events with EES results in a
better clinical outcome as compared with the ULMD PCI
and surgical cohorts of the SYNTAX trial.
The outcomes after PES implantation in this study are
similar to the ones reported by the multicenter TRUE
(Taxus in Real-life Usage Evaluation) registry and the
ISAR-Left Main (Intracoronary Stenting and Angio-
graphic Results: Left Main) trial that used the same first-
EES
(n  166) p Value Unadjusted HR (95% CI)
17 (10.2) 0.002 0.45 (0.26–0.78)
8 (4.8) 0.345
2 (1.2) 0.397
7 (4.2) 0.002
7
0
0 0.222
13 (7.8) 0.001 0.36 (0.20–0.67)
3 (1.8) 0.071 0.33 (0.09–1.17)
0
3
(n 158)
155 (98) 0.609
8 (5.2) 0.002
erse cardiovascular event(s); MImyocardial infarction; TVF target vessel failure; TVR targetgeneration PES (12,14).
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October 2, 2012:1217–22 Stent Comparison for Left Main PCIThis study confirmed the superiority of EES over PES in
ULMD but at a higher degree as compared with previous
randomized trials, with a dramatic decrease in the risk of
restenosis and TVR rate (1–4). It is likely that in the subset
of patients with ULMD, where the target lesion in the
majority of cases involves a bifurcation or a trifurcation and
is associated with multivessel disease requiring multivessel
intervention, the benefit provided by EES as compared with
PES may be increased as compared with the benefit shown
in randomized trials that included patients with lesions at
lower risk of TVF.
In this study, the 1-year MACE rate of 10.2% compares
favorably with the MACE rates revealed in the left main
subset of the SYNTAX trial (6). In the SYNTAX trial, the
1-year MACE rate was 15.8% in the PES-PCI arm and
13.6% in the coronary artery bypass grafting arm (6). This
difference may be more relevant when considering that the
left main SYNTAX patient cohort had a better risk profile
as compared with the Florence registry (EuroSCORE: 3.8
and 6.8, respectively). Again, the restenosis rate of 5.2%
compares favorably with the 8% reported in the
SYNTAX-LE MANS (SYNergy Between PCI With
TAXus Express and Cardiac Surgery: Late [15-month] Left
Main Angiographic Substudy) angiographic substudy (15).
However, it should be highlighted that in this study, only
62.2% of patients had distal ULMD.
Study limitations. This is a nonrandomized, single-center
study. However, we used propensity score matching to make
the patient groups comparable according to the measured
confounders. Despite the shortcomings inherent in all
registries, the study provides original insights into the
Baseline Clinical and Angiographic Characteristicsof the Propensity-Matched G oupsTable 4 Baseli e Clin cal and Angiograph c Characteristicsof the Propensity-Matched Groups
PES
(n  166)
EES
(n  166) p Value
Age, yrs 70.6 9.6 70.7 10.5 0.963
Male 125 (75) 128 (77) 0.699
Diabetes mellitus 43 (26) 40 (24) 0.704
Hypercholesterolemia 105 (63) 89 (54) 0.075
Arterial hypertension 125 (75) 115 (69) 0.200
Peripheral vascular disease 35 (21) 34 (21) 0.892
Previous MI 37 (22) 29 (18) 0.369
Unstable angina 79 (48) 67 (40) 0.185
NSTEMI 28 (17) 21 (13) 0.279
Creatinine 150 mol/l 17 (10) 17 (10) 1.000
LVEF 30% 19 (12) 21 (13) 0.751
EuroSCORE 5.7 [3.0–13.8] 6.1 [2.8–12.5] 0.809
EuroSCORE 13 46 (27) 40 (24) 0.452
LM plus 2-vessel disease 72 (43) 68 (41) 0.657
RCA disease 109 (66) 98 (59) 0.213
Distal LM location 141 (85) 151 (91) 0.092
LM stenting of both branches 49 (30) 45 (27) 0.626
Complete revascularization 126 (76) 135 (81) 0.228
Values are mean  SD, n (%), or median [interquartile range]. The chi-square test was used for
omparison of categorical variables, and the unpaired 2-tailed Student t test or Mann-Whitney rank
um test for continuous variables.
Abbreviations as in Tables 1 and 3.clinical and angiographic outcomes after EES and PES
implantation for ULMD.
Conclusions
The results of this study support the hypothesis that the
SYNTAX trial would have been a positive study if the EES
had been used instead of first-generation PES.
Reprint requests and correspondence: Dr. David Antoniucci,
Division of Cardiology, Careggi Hospital, Viale Morgagni, Flor-
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